{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:56:17Z","timestamp":1780937777452,"version":"3.54.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"abstract":"<jats:p>\n                    Cardiovascular disease is the leading global cause of mortality, affecting the development of cognitive impairment in the elderly. Lipid-lowering drugs are commonly used to manage cardiovascular disease risk, but their effects on cognitive performance have produced conflicting results in previous research. To better guide the selective decision-making and application of lipid-lowering drugs, this study aims to determine the causal relationship between lipid-lowering drugs and cognitive performance through Mendelian randomization. We conducted a 2-sample Mendelian randomization study based on summary statistics from genome-wide association studies for lipid-lowering drugs and cognitive performance. Single-nucleotide polymorphisms significantly related to low-density lipoprotein cholesterol or triglycerides and associated with drug target genes served as proxies for statins, ezetimibe, proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors, fibrates, etc. Genetically predicted statins (\n                    <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                    \u2005=\u2005\u22120.094, 95% confidence interval \u22120.138 to \u22120.049,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and ezetimibe (\n                    <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                    \u2005=\u2005\u22120.319, 95% confidence interval \u22120.408 to \u22120.231,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) had adverse effects on cognitive performance, while other drugs, including PCSK9 inhibitors and fibrates, etc showed no significant impact. This study suggests that statins and ezetimibe may have adverse effects on cognition, while PCSK9 inhibitors and fibrates appear to have no such effect, which may help clinicians make more informed prescription decisions. These findings should be interpreted carefully and require further validation by long-term follow-up clinical studies.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044260","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:12:01Z","timestamp":1757355121000},"page":"e44260","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Are lipid-lowering drugs harmful to cognitive performance?: A Mendelian randomization study"],"prefix":"10.1097","volume":"104","author":[{"given":"Lijun","family":"Han","sequence":"first","affiliation":[{"name":"Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"},{"name":"Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"\u201cChuangxin China\u201d Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Su","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"},{"name":"Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"\u201cChuangxin China\u201d Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruonan","family":"Lian","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"},{"name":"Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"\u201cChuangxin China\u201d Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junming","family":"Han","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"},{"name":"Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"\u201cChuangxin China\u201d Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiude","family":"Fan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"},{"name":"Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"\u201cChuangxin China\u201d Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Gao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China"},{"name":"Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Institute of Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"\u201cChuangxin China\u201d Innovation Base of Stem Cell and Gene Therapy for Endocrine Metabolic Diseases, Jinan, Shandong Province, China"},{"name":"Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251029","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study.","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R2-20251029","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.arr.2014.07.003","article-title":"Cognitive impairment and cardiovascular diseases in the elderly. A heart-brain continuum hypothesis.","volume":"18","author":"Abete","year":"2014","journal-title":"Ageing Res Rev"},{"key":"R3-20251029","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","article-title":"Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function.","volume":"80","author":"Rosoff","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R4-20251029","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1345\/aph.1H014","article-title":"Simvastatin-induced decline in cognition.","volume":"40","author":"Padala","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R5-20251029","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1592\/phco.23.15.1663.31953","article-title":"Cognitive impairment associated with atorvastatin and simvastatin.","volume":"23","author":"King","year":"2003","journal-title":"Pharmacotherapy"},{"key":"R6-20251029","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults.","volume":"117","author":"Muldoon","year":"2004","journal-title":"Am J Med"},{"key":"R7-20251029","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jgs.12414","article-title":"Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment.","volume":"61","author":"Steenland","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"R8-20251029","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000319647.15752.7b","article-title":"Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.","volume":"71","author":"Cramer","year":"2008","journal-title":"Neurology"},{"key":"R9-20251029","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.neurobiolaging.2007.09.012","article-title":"Serum total cholesterol, statins and cognition in non-demented elderly.","volume":"30","author":"Solomon","year":"2009","journal-title":"Neurobiol Aging"},{"key":"R10-20251029","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jagp.2019.11.003","article-title":"Statin use and risk of cognitive decline in the ADNI cohort.","volume":"28","author":"Kemp","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"key":"R11-20251029","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.","volume":"30","author":"Ott","year":"2015","journal-title":"J Gen Intern Med"},{"key":"R12-20251029","doi-asserted-by":"crossref","first-page":"105155","DOI":"10.1016\/j.neubiorev.2023.105155","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the central nervous system.","volume":"149","author":"Bell","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"R13-20251029","doi-asserted-by":"crossref","first-page":"100426","DOI":"10.1016\/j.jlr.2023.100426","article-title":"PCSK9 and the nervous system: a no-brainer?","volume":"64","author":"Jaafar","year":"2023","journal-title":"J Lipid Res"},{"key":"R14-20251029","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/eurheartj\/ehx661","article-title":"No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.","volume":"39","author":"Harvey","year":"2018","journal-title":"Eur Heart J"},{"key":"R15-20251029","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab.","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20251029","doi-asserted-by":"crossref","first-page":"e026122","DOI":"10.1161\/JAHA.122.026122","article-title":"Comparing the relationships of genetically proxied PCSK9 inhibition with mood disorders, cognition, and dementia between men and women: a drug-target Mendelian randomization study.","volume":"11","author":"Bell","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"R17-20251029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25642","article-title":"Lipid lowering and Alzheimer disease risk: a Mendelian randomization study.","volume":"87","author":"Williams","year":"2020","journal-title":"Ann Neurol"},{"key":"R18-20251029","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R19-20251029","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R20-20251029","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization.","volume":"318","author":"Emdin","year":"2017","journal-title":"JAMA"},{"key":"R21-20251029","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00125-021-05645-7","article-title":"Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study.","volume":"65","author":"Zhao","year":"2022","journal-title":"Diabetologia"},{"key":"R22-20251029","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels.","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"R23-20251029","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41588-018-0147-3","article-title":"Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.","volume":"50","author":"Lee","year":"2018","journal-title":"Nat Genet"},{"key":"R24-20251029","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/mp.2017.197","article-title":"GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report from the COGENT consortium.","volume":"22","author":"Trampush","year":"2017","journal-title":"Mol Psychiatry"},{"key":"R25-20251029","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease.","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"R26-20251029","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"R27-20251029","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator.","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"R28-20251029","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/sim.6522","article-title":"Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome.","volume":"34","author":"Greco","year":"2015","journal-title":"Stat Med"},{"key":"R29-20251029","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"An assessment by the Statin Cognitive Safety Task Force: 2014 update.","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R30-20251029","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of statin therapy.","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"R31-20251029","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"R32-20251029","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/15548627.2017.1356977","article-title":"Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.","volume":"13","author":"Kim","year":"2017","journal-title":"Autophagy"},{"key":"R33-20251029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2011.10.029","article-title":"Peroxisome proliferator-activated receptor-\u03b1 activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.","volume":"674","author":"Bhateja","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"R34-20251029","doi-asserted-by":"crossref","first-page":"e003153","DOI":"10.1161\/CIRCOUTCOMES.116.003153","article-title":"Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors.","volume":"10","author":"Khan","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R35-20251029","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","article-title":"Cognition after lowering LDL-cholesterol with evolocumab.","volume":"75","author":"Gencer","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:04:37Z","timestamp":1761750277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":35,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044260","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"2024-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}